Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | WDR5 | P61964 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674524 | 1.00 | LMNA (0.59) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL29434730 | 0.90 | DRD2 (0.58) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL2963485 | 0.90 | DRD2 (0.58) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL1281910 | 0.89 | DRD2 (0.57) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL9808215 | 0.87 | LMNA (0.67) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL10632624 | 0.87 | HRH3 (0.57) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL8155382 | 0.85 | SMN1; SMN2 (0.50) | MAPK1SMN1; SMN2CYP2D6 | |
| SCHEMBL1685432 | 0.82 | DRD2 (0.62) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL3957187 | 0.82 | LMNA (0.61) | LMNAMAPK1HTTSMN1; SMN2DRD2 | |
| SCHEMBL9808100 | 0.82 | DRD2 (0.72) | LMNAMAPK1HTTSMN1; SMN2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117105872-A | Benzodiazepine compound and preparation method and application thereof | 徐州医科大学 | 2023-11-24 | — | — | CN | claimed |
| EP-3233077-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12428373-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| CN-117105872-A | Benzodiazepine compound and preparation method and application thereof | 徐州医科大学 | 2023-11-24 | — | — | CN | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11498896-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| EP-3233799-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2021-05-19 | — | — | EP | disclosed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| US-5760035-A | PIPERIDINE COMPOUNDS SUBSTITUTED WITH AN AMINOALKYL GROUP AND AN ARYLOXYALKYL GROUP, ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, IMMUNOSUPPRESSANTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-06-02 | — | — | US | disclosed |
| EP-0720602-B1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1997-07-09 | — | — | EP | disclosed |
| EP-0720602-A1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995008535-A1 | 4-ALKYLAMINO-1-PHENOXYALKYL PIPERIDINES AS ANTIINFLAMMATORY, ANTIALLERGIC AND IMMUNOMODULATING AGENTS | KNOLL AG (DE) | 1995-03-30 | — | — | WO | disclosed |
| EP-0445026-B1 | Aminomethylpiperidine derivatives, their process for preparation and the pharmaceutical compositions containing them | ADIR (FR) | 1994-01-26 | — | — | EP | disclosed |
| US-5229399-A | Analgesics | ADIR ET COMPAGNIE (FR) | 1993-07-20 | — | — | US | disclosed |
| US-5229398-A | Analgesics | ADIR ET COMPAGNIE (FR) | 1993-07-20 | — | — | US | disclosed |
| US-5192775-A | Analgesics | ADIR ET COMPAGNIE (FR) | 1993-03-09 | — | — | US | disclosed |
| EP-0445026-A1 | Aminomethylpiperidine derivatives, their process for preparation and the pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1991-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498896-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | LMNA 4865/4885MAPK1 1641/4885HTT 536/4885 |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | LMNA 4865/4885MAPK1 1641/4885HTT 536/4885 |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | LMNA 4865/4885MAPK1 1641/4885HTT 536/4885 |
| US-12428373-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | LMNA 4865/4885MAPK1 1641/4885HTT 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.